Posted by Michael Wonder on 06 Nov 2020
ICER publishes evidence report on new therapies for bladder cancer
6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care was able to be determined for either nadofaragene firadenovec or oportuzumab monatoxs; the evidence is also inadequate to enable a clear comparison of these treatments to each other or to other active treatments.
The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and value of nadofaragene firadenovec (Adstiladrin, FKD Therapies Oy and FerGene) and oportuzumab monatox (Vicineum, Sesen Bio) for the treatment of non-muscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin (BCG) intravesical therapy.
